Management of CLL and the Role of Minimal Residual Disease (MRD)

Management of CLL and the Role of Minimal Residual Disease

Presented by Dr. Matthew Davids, MD, MMSc

Associate Director of the CLL Center

Dana-Farber Cancer Institute

Objectives:

• Examine the data supporting MRD as a prognostic marker
• Highlight the increasing relevance of MRD as a response assessment tool in the context of novel therapies
• Explore practical questions related to the use of MRD, such as how to define "undetectable" MRD
• Present the features of different resting methodologies
• Discuss the clinical situations and patient types in which MRD may be used to inform clinical management